A contract with Naprogenix Inc that is assessing the ability of extracted tobacco alkaloids which inhibit VMAT2 activity to serve as potential pharmacotherapeutics for alcohol and nicotine use disorders.
Functional and Genomic Signatures of Escalated Fentanyl Use (R01 DA053070)
A collaborative project with Dr Pavel Ortinski and Dr Jill Turner at the University of Kentucky examining the connection between individual behavioral variability in escalation of fentanyl use and genomic and functional networks in the nucleus accumbens and prefrontal cortex.
HOME TEACHING COURSES RESEARCH LABORATORY
Emily Denehy
emily.denehy@uky.edu
Last Updated:
3/4/25